Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00405093|
Recruitment Status : Completed
First Posted : November 29, 2006
Last Update Posted : January 19, 2017
Primary Objective: The aim of this study is to assess the effects of Aprotinin (an antifibrinolytic drug used to reduce bleeding during cardiac surgery) on renal function in patients undergoing surgery with use of hypothermic bypass and circulatory arrest for repair of the thoracic aorta.
Secondary Objective: To compare the effects of Aprotinin and Amicar on major vascular outcomes following thoracic aorta surgery with use of hypothermic bypass and circulatory arrest.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||1250 participants|
|Official Title:||Aprotinin Use and Renal Outcome in Hypothermic Bypass and Circulatory Arrest for Surgical Repair of Thoracic Aorta. A Retrospective Study.|
|Study Start Date :||July 2006|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||May 2013|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00405093
|United States, New York|
|The New York Presbyterian Hospital - Weill Medical College of Cornell University|
|New York, New York, United States, 10021|
|Principal Investigator:||James Osorio, MD||Associate Professor|